Reviews on recent clinical trials最新文献

{"title":"Preface.","authors":"Luigi Boccuto","doi":"10.2174/011574887112688260922110800","DOIUrl":"https://doi.org/10.2174/011574887112688260922110800","url":null,"abstract":"","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Biomarkers and Novel Therapeutics in Renal Cell Carcinoma: Evidence from Recent Clinical Trials.","authors":"Bida Joshua John, Shoma Mukherjee, Pallavi Prasad, Anisha Adya, Ratnakar Shukla","doi":"10.2174/0115748871512585261007153038","DOIUrl":"https://doi.org/10.2174/0115748871512585261007153038","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is the most common renal malignancy in adults. Owing to its high incidence, asymptomatic presentation, late diagnosis, and resistance to conventional therapies, it is associated with significant morbidity and mortality. However, current clinical trials focus more on identifying suitable molecular biomarkers and evaluating new treatments, such as targeted agents and immunotherapy. This review highlights novel biomarkers and recent clinical trials for the therapeutic management of patients with RCC. A comprehensive literature review was conducted using databases such as Web of Science, MEDLINE, Scopus, PubMed, and ClinicalTrials.gov (https://clinicaltrials.gov/) on novel biomarkers and various clinical trials for RCC. Recent clinical trials have shown a significant increase in biomarker discovery, including DNA methylation, microRNAs, long non-coding RNAs, and protein-based markers, which influence diagnosis, prognosis, and treatment. The treatment of RCC has progressed from cytokine-based immunotherapy to targeted therapies, such as mTOR and VEGF inhibitors, immune checkpoint inhibitors, and combination regimens, which have greatly improved patient outcomes. Emerging approaches, including novel immunological targets, adoptive cell therapies, vaccines, and oncolytic virotherapy, hold promise for overcoming resistance and boosting efficacy, and are currently being investigated in clinical trials. Despite these developments, intratumoral heterogeneity, lack of prognostic biomarkers, disparities in clinical trials, and treatment resistance are major limitations. Ongoing research and clinical trials focused on biomarker-driven precision medicine and combination approaches are expected to improve RCC management significantly. Validation through large multicenter trials will be necessary to enable the use of biomarkers for precision medicine in routine practice.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Hypoxic-ischaemic Encephalopathy and Takotsubo Cardiomyopathy Following Accidental Butane Exposure: A Case Report.","authors":"Simona Paola Tiburzi, Rosetta Nistico', Vincenzo Stivala, Archina De Luca, Isora Justiz-Pérez, Antonella Putignano, Virginia Vescio","doi":"10.2174/0115748871514679261009113338","DOIUrl":"https://doi.org/10.2174/0115748871514679261009113338","url":null,"abstract":"<p><strong>Background: </strong>Butane is a highly lipophilic aliphatic hydrocarbon widely used as a domestic fuel and aerosol propellant. Acute exposure in enclosed environments may cause severe neurological and cardiovascular toxicity through oxygen displacement, respiratory depression, myocardial sensitisation to catecholamines, and potentially direct toxic effects.</p><p><strong>Case presentation: </strong>A 45-year-old woman was found unconscious in a small, closed studio apartment, while her husband was found deceased in the same environment. Subsequent inspection by the judicial authorities identified deterioration of the gas tubing associated with a gas leak. The patient presented in deep coma (Glasgow Coma Scale score 5) and required tracheal intubation and mechanical ventilation. Initial carboxyhaemoglobin was 16.9% and progressively normalised during oxygen therapy. Brain imaging demonstrated extensive cortical, deep grey matter, brainstem, cerebellar, and white-matter abnormalities consistent with severe hypoxic-ischaemic injury. Cardiac evaluation showed mild ST-segment elevation, increased cardiac biomarkers, and severe transient Left Ventricular Systolic Dysfunction (LVEF 25%) with a pattern highly suggestive of Takotsubo cardiomyopathy; LVEF subsequently improved to 44%. Severe neurological impairment persisted, and the patient was transferred to neurological rehabilitation. She died approximately six months after the index event; reliable documentation of the precise cause of death was unavailable.</p><p><strong>Conclusion: </strong>This case illustrates the severe neurological and cardiovascular consequences that may follow accidental butane exposure in an enclosed environment. The coexistence of extensive hypoxic- ischaemic brain injury and transient stress-related ventricular dysfunction highlights the importance of integrated neurological, cardiological, and toxicological assessment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Pharmacological Interventions for Huntington's Disease: Evidence from Clinical Translation.","authors":"Varsha Raj, Mohit Gupta, Neerja Kumari, Anubha Gaur, Mukesh Chandra Sharma, Varsha Snehi, Rahul Yadav, Shivendra Kumar, Jeetendra Kumar Gupta","doi":"10.2174/0115748871503552261008112411","DOIUrl":"https://doi.org/10.2174/0115748871503552261008112411","url":null,"abstract":"<p><p>Huntington's Disease (HD) is a rare autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, psychiatric disturbances, and cognitive decline. An expanded CAG trinucleotide repeat in the Huntingtin (HTT) gene causes it to repeat, leading to the production of mutant Huntingtin Protein (mHTT), which drives selective neuronal degeneration, particularly in the striatum and cortex. Despite the identification of its genetic basis over three decades ago, HD remains incurable, with current therapies largely limited to symptomatic management. This review provides a comprehensive overview of emerging pharmacological strategies targeting the underlying molecular and cellular mechanisms of HD, with emphasis on translational insights from recent and ongoing clinical trials. Key pathogenic processes, including protein aggregation, transcriptional dysregulation, impaired proteostasis, mitochondrial dysfunction, synaptic deficits, and chronic neuroinflammation, are discussed to contextualize therapeutic approaches. Genetargeting strategies, including Antisense Oligonucleotides (ASOs), RNA interference (RNAi), and small-molecule splicing modulators, have demonstrated effective suppression of mutant huntingtin expression and favorable biomarker responses. However, despite robust target engagement, these molecular effects have not consistently translated into sustained clinical benefit, highlighting the complexity of achieving disease modification in Huntington's disease. Similarly, therapies targeting neuroinflammation, autophagy, mitochondrial dysfunction, and synaptic signaling have shown encouraging preclinical efficacy but only limited clinical success. The review highlights the critical role of biomarkers, including cerebrospinal fluid mHTT, neurofilament light chain, and imaging markers, in evaluating therapeutic efficacy, while underscoring the uncertainty in their correlation with long-term clinical outcomes. Persistent challenges in clinical translation emphasize the need for precision-based, stage-specific therapeutic strategies to achieve meaningful disease modification. Unlike previous reviews, this article critically integrates recent clinical trial outcomes with translational challenges, biomarker validation, regulatory perspectives, and future precision-medicine strategies, providing a comprehensive overview of the evolving therapeutic landscape for Huntington's disease.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genital Tuberculosis (GTB): Insights into Diagnosis, Treatment, Clinical Trials and Patents-A Comprehensive Review.","authors":"Anuradha Singh, Prottay Dutta, Mohammad Muztaba, Swagatam Sahoo, Pooja Ganeshdas Bhutada, Manju, K P Selma Thasni, Binita Ghosh, Rahul Pal","doi":"10.2174/0115748871502522261008104215","DOIUrl":"https://doi.org/10.2174/0115748871502522261008104215","url":null,"abstract":"<p><p>Genital Tuberculosis (GTB) represents a frequently unrecognized type of extrapulmonary Tuberculosis (TB) that affects the female reproductive system. The condition results in infertility, menstrual cycle disturbances, and pelvic pain. The condition is difficult to detect at an early stage because its mild symptoms can manifest in different body parts. Therefore, medical professionals require better methods for diagnosing and treating patients. This review aims to provide a comprehensive overview of the epidemiology, pathogenesis, clinical manifestations, diagnostic approaches, therapeutic strategies, and current advancements in the management of GTB. The study presents information on New Drug Delivery systems (NDDs), current clinical trials, and new patents to guide future research. A literature-based narrative review was conducted, focusing on peer-reviewed articles, clinical studies, patents, and recent advances in diagnostics and therapeutics of GTB. The study focused on three main areas: anatomical site-specific manifestations; laboratory instruments and drug medications. The fallopian tubes are the most commonly affected site (90-100%), followed by the endometrium (50-60%), ovaries (20-30%), cervix (5-10%), while involvement of the vagina and vulva is rare (<1%). The diagnosis of GTB becomes problematic because both its visible and hidden symptoms start to appear. The development of effective detection methods depends on both traditional diagnostic methods and modern molecular methods, which include specialized laboratory equipment, imaging techniques, and histopathology. Current clinical trials and new patent approvals demonstrate the development of new methods for diagnosing and treating GTB, including improved therapeutic approaches and drug delivery systems. GTB presents both diagnostic and treatment difficulties because patients show different symptoms that can remain hidden. The combination of methods for diagnosing and treating GTB, through improved therapeutic approaches and drug-delivery systems, will enhance detection, treatment outcomes, and the ability to maintain fertility. The research should investigate personalized medicine approaches, molecular diagnostic technologies, and new therapeutic delivery systems to address the existing clinical needs in GTB treatment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review Article on Smart Phyto-nanoemulgel Systems for Modulation of Inflammatory Mediators in Rheumatoid Arthritis.","authors":"Renu Tiwari, Shaweta Sharma","doi":"10.2174/0115748871495317260907100938","DOIUrl":"https://doi.org/10.2174/0115748871495317260907100938","url":null,"abstract":"<p><p>This review article offers a thorough examination of nanoemulgel-based drug delivery methods for rheumatoid arthritis (RA) treatment. The study delves into the fusion of nanotechnology with gel-based systems, underscoring their superior drug-delivery capabilities, controlled release, and targeted therapeutic potential for managing rheumatoid arthritis. It also provides a detailed exploration of the use of herbal plants in the treatment of arthritis, focusing on traditional remedies, active components, mechanisms of action, and pharmacological strategies to enhance their administration. These approaches are designed to improve bioavailability, support targeted distribution, and allow for controlled release of herbal constituents. Safety considerations, including potential drug interactions and the risk of allergic responses, are also addressed. Rheumatoid arthritis is a debilitating condition characterized by inflammation of the synovial membrane, leading to cartilage and bone degradation. Numerous medications, including anti-inflammatory drugs and disease-modifying antirheumatic therapies, can assist in its management; also, phytotherapy presents a promising and advantageous approach for treating rheumatoid arthritis, due to its capacity to target a range of inflammatory substances, such as nitric oxide (NO), cytokines, chemokines, and adhesion molecules, especially given the significant side effects associated with conventional treatments. Additionally, nanomedicine offers a valuable formulation approach to address challenges associated with phytoconstituents, including poor bioavailability, high first-pass metabolism, and reduced stability. This review provides an extensive overview of numerous phytoconstituents with significant potential in the management of RA, their limitations, innovative drug formulations reported, and the relevant regulatory considerations.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence and Generative AI in Clinical Trials for Autism and Other Neurobehavioral Disorders.","authors":"Mattia Galanti, Luigi Boccuto","doi":"10.2174/0115748871524685260904061932","DOIUrl":"https://doi.org/10.2174/0115748871524685260904061932","url":null,"abstract":"<p><p>Artificial Intelligence (AI) provides remarkable tools in modern medicine and is widely used to process high-throughput data and integrate different omics-derived models. In recent years, AI, and particularly generative AI (GenAI), has been utilized to design clinical trials for neurobehavioral disorders due to the complexity of variables presented by these conditions. However, ethical and methodological limitations suggest a supporting rather than leading role of AI in the design, management, and interpretation of clinical trials, and caution against moving the human component away from the evaluation of the qualitative as well as quantitative impact of a new treatment protocol.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proactive Safety Monitoring of Biosimilars: A Comprehensive Approach Combining Immunogenicity, Big Data, and Global Standards.","authors":"Megha Naudiyal, Arzoo Pannu, Shivang Gangotri, Utkarsh Kumar, Sunny Kumar Rao","doi":"10.2174/0115748871503065260901071735","DOIUrl":"https://doi.org/10.2174/0115748871503065260901071735","url":null,"abstract":"<p><p>The introduction of biosimilars into the marketplace has allowed more patients access to biological drugs through the development of alternative, but highly similar biological products. However, the complex nature of biosimilars in terms of structure, manufacture, and risk of immunogenicity requires strong and continual pharmacovigilance throughout the lifecycle of these biological products. The present review seeks to offer a comprehensive insight into existing pharmacovigilance practices for biosimilars, with a particular focus on immunogenicity, post-market surveillance, real-world evidence, digital technology, traceability, and regulatory practices. A narrative review was performed on relevant literature identified from PubMed, Scopus, Web of Science, and Google Scholar, alongside guidance and regulation on biosimilar pharmacovigilance from relevant regulatory agencies. This review indicates that successful pharmacovigilance for biosimilars necessitates the use of an approach that combines spontaneous adverse event reporting, active post-market surveillance, immunogenicity evaluation, real-world evidence, risk management, and product traceability. Novel strategies using artificial intelligence, machine learning, digital health tools, blockchain technology for traceability, and pharmacoepidemiology could enhance signal detection, better understand product identification, conduct long-term safety evaluations, and implement risk management. There still exist several challenges connected with data quality, interoperability, confidentiality, infrastructure, harmonization of regulations, and standardized approaches to biosimilar safety monitoring. Thus, an active, lifecycle-based pharmacovigilance system that integrates immunogenicity surveillance, real-world evidence, digital technologies, and standardized regulation is essential for improved biosimilar pharmacovigilance and clinical use of biosimilars.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Differences in Cardiovascular Health-related Attitudes, Beliefs, and Behaviors: The Mediating Role of Perceived Risk in Health-promoting Lifestyles - A Health Belief Model Approach.","authors":"Ramya Kundayi Ravi, Mona Gamal Mohamed, Rose Ekama Ilesanmi, Aleena Mary Jaison, Sooud Hussein Ali, Aleena AjI, Alvymol Anish","doi":"10.2174/0115748871436343260206222650","DOIUrl":"https://doi.org/10.2174/0115748871436343260206222650","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, including in the United Arab Emirates (UAE). This study aimed to assess the attitudes, beliefs, and health-promoting behaviors (HPB) related to CVD among adults.</p><p><strong>Methods: </strong>This exploratory survey was conducted among 707 adults recruited using a convenience sampling technique from the Northern Emirate of the United Arab Emirates. A structured questionnaire based on the Health Belief Model, containing a sociodemographic data sheet, Attitudes and Beliefs about Cardiovascular Disease Risk (ABCD) Questionnaire, and Health-Promoting Lifestyle Profile (HPLP-II) were used to collect the data.</p><p><strong>Results: </strong>Adults demonstrated moderate levels of attitudes and beliefs, as reflected in ABCD scores (46.10 ± 3) and health-promoting lifestyle behaviors (131.54 ± 28.06). Gender differences were observed in attitudes, beliefs about CVDs, and health-promoting behaviors. Females had significantly higher knowledge scores (7.03 ± 1.7) than males (6.32 ± 2.08), t (705) = 4.46, p < 0.001, and greater health responsibility (t = 2.41, p = 0.016). Moderated mediation analysis (PROCESS Model 7) revealed that knowledge positively predicted perceived risk (β = 0.32, p < 0.001) and HPBs (β = 0.29, p < 0.001), perceived risk negatively predicted PHRs (β = -0.24, p < 0.001), and perceived benefit significantly moderated the knowledge-risk relationship (β = -0.11, p = 0.001).</p><p><strong>Discussion: </strong>Knowledge, perceived risk, and perceived benefit are found to be factors influencing health-promoting behaviours. A signiifacnt geneder differences were observed in the knowledge and health responsibility among the study population.</p><p><strong>Conclusion: </strong>The findings suggest the need for improving the cardiovascular knowledge, attitude, and health-promoting behaviours in the study population. Policies should support comprehensive, gender-specific, and culturally appropriate cardiovascular health promotion interventions to effectively address these gaps.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant Hydronephrosis Secondary to Ureteral Obstruction Imposed by Massive Hepatomegaly in a Patient with Polycystic Liver Disease: A Case Report.","authors":"Konstantinos Tzelepis, George Vartzelis, Konstantinos Stamatiou, Emmanouil Manolakos, Ilias Giannakodimos, Vasileios Langouretos, Charalampos Kotoulas, Panagiotis Venieris, Afroditi Ziogou, Nikolaos Stylianidis, Kiriaki Tsakali, Dimitra Stamouli, Sotirios Sotiriou, George Meimaris","doi":"10.2174/0115748871502549260825233616","DOIUrl":"https://doi.org/10.2174/0115748871502549260825233616","url":null,"abstract":"<p><strong>Background: </strong>Polycystic liver disease is a genetic pathology characterized by the formation of numerous cysts in the liver. This case is notable for the rare presentation of isolated polycystic liver disease leading to secondary obstructive uropathy. Unlike the more common association with autosomal dominant polycystic kidney disease, this patient exhibited no evidence of bilateral polycystic kidney disease; the only renal finding was a solitary simple cyst in the contralateral kidney, considered an incidental finding, highlighting an unusual extrinsic mechanism of urinary tract obstruction due to massive hepatomegaly. In adults, polycystic liver disease often manifests as an extra-renal complication of autosomal dominant polycystic kidney disease. In rare cases, however, it may present solely as autosomal dominant polycystic liver disease without renal involvement.</p><p><strong>Case presentation: </strong>In this study, we describe a patient with isolated polycystic liver disease, in whom marked hepatomegaly progressively compressed and displaced the kidney, obstructing the ureter at the pyeloureteral junction. Imaging studies, including abdominal ultrasound and computed tomography, confirmed the extent of cystic involvement and the resulting mass effect. This led to the gradual development of severe hydronephrosis, evident both on palpation and during clinical examination of the abdomen. Hydronephrosis, in turn, exerted pressure on adjacent organs such as the liver, pancreas, stomach, and large vessels, causing symptoms including abdominal distension, dysphagia, gastroesophageal reflux, early satiety, reduced mobility, as well as abdominal and lumbar pain.</p><p><strong>Conclusion: </strong>Clinicians should consider the possibility of mass effect complications in patients with isolated polycystic liver disease, as early recognition and intervention may help prevent severe secondary organ dysfunction.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}